AS
Aasif Shah
About Aasif Shah
Aasif Shah has 10 years in corporate governance. Holds Director role. Currently with 2 companies, including Front Pocket Ventures Private Limited and Yesteq Ventures Private Limited. Formerly with 2 companies, such as Epillo Health Systems Private Limited and Stetho Health Systems Private Limited. Engaged in General Business, Healthcare. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Front Pocket Ventures Private Limited
U74999DL2016PTC303804
|
Director | 01 Aug 2016 | 2016 | Active |
|
Yesteq Ventures Private Limited
U62013DL2023PTC411801
|
Director | 30 Mar 2023 | 2023 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Epillo Health Systems Private Limited
U85110DL2021PTC382936
|
Director | 29 Jun 2021 | 2021 | Active |
|
Stetho Health Systems Private Limited
U74999PB2017PTC047018
|
Director | 26 Sep 2017 | 2017 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Aasif Shah
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aasif Shah
Aasif Shah has 10 years in corporate governance. Holds Director role. Currently with 2 companies, including Front Pocket Ventures Private Limited and Yesteq Ventures Private Limited. Formerly with 2 companies, such as Epillo Health Systems Private Limited and Stetho Health Systems Private Limited. Engaged in General Business, Healthcare. Contributes to corporate operations.
Aasif Shah is associated with 2 companies as Director.
Aasif Shah has expertise in General Business, Healthcare.
Aasif Shah has 10 years in corporate governance.